LimmaTech Biologics
About LimmaTech Biologics
LimmaTech Biologics is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, that develops vaccines targeting antimicrobial resistant pathogens. The company leverages its proprietary self-adjuvanting and multi-antigen vaccine platform to advance next-generation vaccines and clinical candidates. With a focus on preventing untreatable microbial infections, LimmaTech aims to deliver protective solutions and advance a robust product pipeline worldwide.
Recent News
Lilly Gets Back in Infectious Disease, via Three M&A Deals
STAT+: Pharmalittle: We’re Reading About a Lilly Gene Therapy for Cholesterol, Three New Lilly Deals, and More
Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B
STAT+: Eli Lilly to Buy Three Small Vaccine Developers
The Biotech Bi-Weekly: Unveiling a New Brain Organoid Assay, Advancing Epigenomics Research and Building an Infectious Disease Research Portfolio
Lilly Just Bought Renowned Regulator Peter Marks a Pipeline to Play With
Recent Deals
No recent deals for this company.